Servier Reports 37.2-Month PFS With VORANIGO in IDH-Mutant Glioma

Share on Social Media

Servier VORANIGO (vorasidenib) Phase 3 INDIGO trial long-term results in IDH-mutant glioma presented at SNO 2026.
Image: Pixels

Servier reports 37.2-month crossover PFS with VORANIGO in the Phase 3 INDIGO trial, alongside tumour response, seizure and safety findings at SNO 2026.

Written By: Neha Vishwakarma, PharmD

Reviewed By: Pharmacally Editorial Team

Servier announced on November 17, 2026, extended follow-up and subgroup results from the Phase 3 INDIGO trial, demonstrating sustained disease control with VORANIGO (vorasidenib) in patients with Grade 2 IDH-mutant glioma. The updated analyses evaluated outcomes in patients who crossed over from placebo alongside new findings on tumour response, seizure activity, and quality of life.

Among patients who crossed over from placebo to VORANIGO, median progression-free survival (PFS) reached 37.2 months, while a post hoc analysis showed a shift from tumour growth to shrinkage after treatment initiation. In the overall population, the objective response rate (ORR) rose from 10.7% to 20.8% with extended follow-up. Separate exploratory analyses also pointed to sustained reductions in seizure frequency and a lower risk of quality-of-life deterioration.

About VORANIGO (Vorasidenib)

VORANIGO (40 mg tablets) is an oral prescription therapy indicated for adult and paediatric patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma harbouring an IDH1 or IDH2 mutation following surgery. Key safety risks include hepatotoxicity, requiring liver-function monitoring prior to and throughout treatment. Common adverse reactions include elevated liver enzymes, fatigue, headache, musculoskeletal pain, diarrhoea, nausea, and seizures. Safety and efficacy in children under 12 years of age have not been established.

INDIGO Study Design

INDIGO is a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating vorasidenib in patients with post-surgical Grade 2 IDH1/2-mutant glioma. Using a January 17, 2025, data cutoff, the updated analyses evaluated 144 of the 163 patients originally assigned to placebo who subsequently crossed over to VORANIGO.

These data build upon extended follow-up findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which reported a median PFS of 44.1 months among patients initially randomized to vorasidenib at a median follow-up of 41.6 months. At the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia, Timothy F. Cloughesy, M.D., presented the crossover and histological subgroup analyses on November 14, followed by Wolfgang Wick, M.D., presenting the exploratory seizure and quality-of-life data on November 15.

Key Results

  • Crossover progression-free survival: Median investigator-assessed PFS was 37.2 months across all crossover patients (95% CI, 33.4 months to not estimable). Median PFS was also 37.2 months in the astrocytoma subgroup and was not reached in the oligodendroglioma subgroup. Patients experiencing progressive disease at the time of crossover achieved a median PFS of 33.4 months.
  • Tumour-volume changes: In a post hoc analysis, mean tumour volume increased by 16.1% per six months prior to crossover, reversing to a 2.9% decrease per six months following VORANIGO initiation. This shift from growth to shrinkage occurred across both astrocytoma and oligodendroglioma subtypes.
  • Objective response rate: Blinded independent review committee (BIRC)-assessed ORR in the overall population increased from 10.7% in September 2022 to 20.8% in January 2025, reflecting cumulative responses over time. Subgroup ORRs rose from 7.5% to 17.5% in astrocytoma and from 13.6% to 23.9% in oligodendroglioma.
  • Seizure control: In the exploratory analysis, the proportion of VORANIGO-treated patients experiencing on-treatment seizures remained stable between March 2023 and January 2025 (98.1% vs 98.2%), while the overall seizure rate declined from 18.2 to 15.9 events per person-year. Consequently, the seizure rate ratio versus placebo improved from 0.36 (95% CI, 0.14–0.89; P=0.0263) to 0.28 (95% CI, 0.14–0.55; P=0.0002).
  • Quality of life: Among patients with more than one seizure, VORANIGO was associated with a reduced risk of deterioration on the Functional Assessment of Cancer Therapy-Brain (FACT-Br) total scale (HR=0.38; 95% CI, 0.15–1.00) and its brain cancer subscale (HR=0.32; 95% CI, 0.11–0.91).
  • Safety: The safety profile remained consistent with prior reports, with no new safety signals identified. Grade 3 or higher treatment-emergent adverse events occurred in 31.7% of patients originally randomized to VORANIGO and 20.1% of crossover patients. The most frequent events were increased alanine aminotransferase (10.8% and 7.6%), aspartate aminotransferase (4.8% and 3.5%), seizures (4.8% and 4.2%), and gamma-glutamyltransferase (3.0% and 0.7%). No treatment-related deaths occurred, and adverse events led to discontinuation in 4.8% and 2.1% of patients, respectively.

Clinical Interpretation

The extended INDIGO data reinforce the durability of disease control with vorasidenib across both major histological subtypes of Grade 2 IDH-mutant glioma. Notably, the reversal of tumour growth trajectory following crossover even among patients with prior disease progression underscores the clinical activity of delayed treatment initiation.

Rising response rates over time and sustained reductions in seizure burden add meaningful clinical context beyond standard radiographic endpoints. Nevertheless, certain methodological caveats apply: the crossover cohort lacked a concurrent control arm, tumour-volume kinetics were evaluated post hoc, and the seizure and quality-of-life analyses were exploratory, with the upper confidence bound of 1.00 for the FACT-Br total scale indicating statistical uncertainty. Consistent with the safety profile, routine liver-function monitoring remains essential, while mature overall survival and longer-term safety follow-up will be critical to fully define long-term benefit.

Reference

Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026, Servier, 17 November 2026

Study of Vorasidenib (AG-881) in Participants with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation (INDIGO), ClinicalTrials.gov ID NCT04164901

About the Writer

Neha Vishwakarma (LinkedIn) is a Pharm.D professional with experience in clinical pharmacy, pharmacovigilance, and clinical research. She has hands-on experience in ADR assessment, ICSR processing, medication safety, and clinical data evaluation. Her research background in surgical site infections and antibiotic use supports her focus on evidence-based healthcare writing.


Share on Social Media
Scroll to Top